What Researchers Did
Researchers conducted a pilot study where ten postmenopausal women with persistent arm lymphedema after breast cancer treatment received 20 hyperbaric oxygen therapy sessions over four weeks to assess its impact on lymphedema volume and related biomarkers.
What They Found
An average 38% reduction in hand lymphedema (-7.4 ml) was observed at the end of hyperbaric oxygen therapy, which persisted for an average of 14.2 months in 8 out of 10 participants. However, total lymphedema volume did not significantly change, although vascular endothelial growth factor-C (VEGF-C) levels increased from baseline (p = 0.004).
What This Means for Canadian Patients
Canadian patients experiencing persistent hand lymphedema after breast cancer treatment might potentially see some reduction in swelling with hyperbaric oxygen therapy. However, this pilot study suggests it may not significantly impact overall arm lymphedema, and further research is needed before widespread clinical application.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada, nor did it involve Canadian researchers or participants.
Study Limitations
This pilot study was limited by its small sample size of ten participants and the focus on a specific population of postmenopausal women with long-standing lymphedema.